A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials

Journal of Clinical Epidemiology

Volumn 51, Issue 2, 1998, Pages 69-79

  Fuks, Abraham ^a,d   Weijer, Charles ^b,c   Freedman, Benjamin ^d   Shapiro, Stanley ^a,d   Skrutkowska, Myriam ^d   Riaz, Amina ^d  

^a MCGILL UNIVERSITY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Clinical trials; Eligibility determination; Ethics; Neoplasms treatment; Patient participation

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; HUMAN; MASTECTOMY; MEDICAL RESEARCH; ONCOLOGY; PATIENT SELECTION; PRIORITY JOURNAL;

BREAST NEOPLASMS; CANADA; CHILD; CLINICAL PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; ETHICS, MEDICAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LINEAR MODELS; PATIENT SELECTION; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 0031935260     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00240-0     Document Type: Article

References (48)

1. Friedman MA, Cain DF National Cancer Institute sponsored cooperative clinical trials. Cancer. 65:1990;2376-2382.
2. American Medical Association Council on Scientific Affairs Viability of cancer clinical research. Patient accrual, coverage, and reimbursement J National Cancer Institute. 83:1991;254-259.
3. Wittes RE, Friedman MA Accrual to clinical trials. (Editorial). J National Cancer Institute. 80:1988;884-885.
4. Frelick RW The Community Clinical Oncology Program (CCOP) story. Review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987 J Clin Oncol. 12:1994;1718-1723.
5. Cobau CD Clinical trials in the community. The Community Clinical Oncology Program experience Cancer. 74(Suppl.):1994;2694-2700.
6. Cottman CA The SWOG experience with CCOP's. J Cancer Program Manage. 1:1986;19-22.
7. Begg CB, Carbone PP, Elson PJ, Zelen M Participation of community hospitals in clinical trials. Analysis of five years of experience in the Eastern Cooperative Oncology Group N Engl J Med. 306:1982;1076-1080.
8. Gotay CC Accrual to cancer research trials. Directions from the research literature Social Sci Med. 33:1991;569-577.
9. Taylor KM, Margolese RG, Soskolne CL Physician's reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med. 310:1984;1363-1367.
10. Mansour EG Barriers to clinical trials. Part III. Knowledge and attitudes of health care providers Cancer. 74(Suppl.):1994;2672-2675.
11. Benson AB III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K Oncologists' reluctance to accrue patients onto clinical trials. An Illinois Cancer Center study J Clin Oncol. 9:1991;2067-2075.
12. Taylor KM, Feldstein ML, Skeel RT, Pandya KJ, Ng P, Carbone PP Fundamental dilemmas of the randomized clinical trial process. Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators J Clin Oncol. 12:1994;1796-1805.
13. Langley GR, Sutherland HJ, Wong S, Minkin S, Llewellyn-Thomas HA, Till JE Why are (or are not) patients given the option to enter clinical trials? Control Clin Trials. 8:1987;49-59.
14. Morrow GR, Hickok JT, Burish TG Behavioral aspects of clinical trials. An integrated framework from behavior theory Cancer. 74(Suppl.):1994;2676-2682.
15. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C Patients' willingness to enter clinical trials. Measuring the association between perceived benefit and preference for decision participation Social Sci Med. 32:1991;35-42.
16. Schain WS Barriers to clinical trials. Part II. Knowledge and attitudes of potential participants Cancer. 74(Suppl.):1994;2666-2671.
17. Llewellyn-Thomas HA, McGreal MJ, Theil EC Cancer patients' decision making and trial-entry preferences. Med Decision Making. 15:1995;4-12.
18. Cassileth BR, Lusk EJ, Miller DSet al. Attitudes towards clinical trials among patients and the public. JAMA. 248:1982;968-970.
19. McCusker J, Wax A, Bennett JM Cancer patient accessions into clinical trials. A pilot investigation into some patient and physician determinants of entry Am J Clin Oncol. 5:1982;227-236.
20. Kotwall CA, Mahoney LJ, Myers RE, Decoste L Reasons for nonentry in randomized clinical trials for breast cancer. A single institution study J Surg Oncol. 50:1992;125-129.
21. Begg CB, Zelen M, Carbone PPet al. Cooperative groups and community hospitals. Measurement of impact in the community hospitals Cancer. 52:1983;1760-1767.
22. Lee JY, Breaux SR Accrual of radiotherapy patients to clinical trials. Cancer. 52:1983;1014-1016.
23. Weijer C The breast cancer research scandal. Addressing the issues Can Med Assoc J. 152:1995;1195-1197.
24. Boros L, Chuange C, Butler FO, Bennett JM Leukemia in Rochester. A 17-year-experience with an analysis of the role of cooperative group (ECOG) participation Cancer. 56:1985;2161-2169.
25. Karjalainen S, Palva I Do treatment protocols improve end results? A study of the survival of patients with multiple myeloma in Finland. Br Med J. 299:1989;1069-1072.
26. Hjorth M, Holmberg E, Rodjer S, Westin J Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma. Br J Haematol. 80:1992;55-61.
27. Weijer C, Freedman B, Fuks A, Robbins J, Shapiro S, Skrutkowska M What difference does it make to be treated on a clinical trial? A pilot study. Clin Invest Med. 19:1996;179-183.
28. Yusuf S, Collins R, Peto R Why do we need large, simple trials? Stat Med. 3:1984;409-420.
29. Sackett DL On some prerequisites for a successful clinical trial. Shapiro S, Louis TA Clinical Trials. Issues and Approaches:1983;65-79 Marcel Dekker, Inc, New York.
30. Yusuf S, Held P, Teo KK Selection of patients for randomized controlled trials. Implications of wide or narrow eligibility criteria Stat Med. 9:1990;73-86.
31. Buyse ME The case for loose exclusion criteria in clinical trials. Acta Chir Belg. 90:1990;129-131.
32. George SL Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 14:1996;1364-1370.
33. Begg CB, Engstrom PF Eligibility and extrapolation in cancer clinical trials. J Clin Oncol. 5:1987;962-968.
34. Fleiss JL Statistical Methods for Rates and Proportions. 2:1981;John Wiley & Sons, New York. 212-236.
35. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. OPRR Reports. April 18, 1979: 1-8.
36. Freedman B, Shapiro S Ethics and statistics in clinical research. Towards a more comprehensive examination J Stat Plan Inference. 42:1994;223-240.
37. Weijer C Evolving ethical issues in the selection of subjects for clinical research. Cambridge Q Healthcare Ethics. 5:1996;334-345.
38. Department of Health and Human Services, National Institutes of Health NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register. 59:1994;14508-14513.
39. Freedman B Multicenter trials and subject eligibility. Should local IRBs play a role? IRB. Review Human Subjects Res 16(1,2):1994;1-6.
40. Kennedy BJ Needed. Clinical trials for older patients J Clin Oncol. 9:1991;718-720.
41. Mor V, Masterson-Allen S, Goldberg RJ, Cummings FJ, Glicksman AS, Fretwell MD Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriat Soc. 33:1985;585-589.
42. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS Choice of cancer therapy varies with age of patient. JAMA. 255:1986;3385-3390.
43. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AN Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois Cancer Center study J Clin Oncol. 12:1994;2447-2452.
44. Christman K, Muss HB, Case LD, Stanley V Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience JAMA. 268:1992;57-62.
45. Weijer C, Fuks A The duty to exclude. Excluding people at undue risk from research Clin Invest Med. 17:1994;115-122.
46. Schwarz D, Lellouch J Explanatory and pragmatic attitudes in therapetic trials. J Chron Dis. 20:1967;637-648.
47. Tate HC, Rawlinson JR Randomized comparative studies in the treatment of cancer in the United Kingdom. Room for improvement? Lancet. ii:1979;623-625.
48. Meadows AT, Kramer S, Hopson R, Lustbader E, Jarret P, Evans AE Survival in childhood acute lymphocytic leukemia. Effect of protocol and place of treatment Cancer Invest. 1:1983;49-55.